JOHNSON & JOHNSON is 2.8x more valuable than Novo Nordisk A/S by market capitalization ($573.98 B vs $202.94 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NVO | JNJ |
|---|---|---|
| Market cap | $202.94 B | $573.98 B |
| US-listed rank | #67 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | - | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 998 | 984 |
JOHNSON & JOHNSON is 2.8x more valuable than Novo Nordisk A/S by market capitalization ($573.98 B vs $202.94 B).
Full pages: Novo Nordisk A/S and JOHNSON & JOHNSON, or browse the full rankings.